Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues. Reply to Nagel JM, Mansmann U, Wegscheider K et al. [letter] and Simon D [letter].
Grouven
U
U
Hemkens
L G
LG
Bender
R
R
Sawicki
P T
PT
D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000627:therapeutic use*; D009369:Neoplasms / Q000139:chemically induced* / Q000453:epidemiology*; D018579:Patient Selection; D018570:Risk Assessment; D012307:Risk Factors
D007004:Hypoglycemic Agents; D007328:Insulin